Bupropion and naltrexone: A review of their use individually and in combination for the treatment of obesity

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 6, 2009, Pages 1069-1081

  Plodkowski, Raymond A ^a   Nguyen, Quang ^a   Sundaram, Umasankari ^a   Nguyen, Loida ^a   Chau, Diane L ^a   St Jeor, Sachiko ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

Bupropion; Contrave ; Naltrexone; Obesity; Weight loss

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; AMFEBUTAMONE; ANTIOBESITY AGENT; CONTRAVE; GLUCOCORTICOID; METERGOLINE; NALTREXONE; NISOXETINE; PHENOXYBENZAMINE; PIMOZIDE; PLACEBO; PROPRANOLOL DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLISM; ANOREXIA; ANXIETY; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOOD PRESSURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; DIZZINESS; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; FOOD INTAKE; HEART RATE; HUMAN; HYPERSOMNIA; INSOMNIA; LIBIDO DISORDER; MALAISE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MONOTHERAPY; MOOD DISORDER; MUSCLE STIFFNESS; MUSCLE WEAKNESS; MYALGIA; NARCOTIC DEPENDENCE; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NONHUMAN; OBESITY; PULSE PRESSURE; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SOMNOLENCE; STOMACH PAIN; SUSTAINED DRUG RELEASE; TRAFFIC ACCIDENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; WEAKNESS; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; BUPROPION; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; NALTREXONE; OBESITY; WEIGHT LOSS;

EID: 67649641596     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902775750     Document Type: Review

References (41)

1. Foster GD, Wadden TA, Phelan S, et al. Obese patients' perceptions of treatment outcomes and the factors that influence them. Arch Intern Med 2001;161:2133-2139 (Pubitemid 36231510)
2. Blackburn GL. Effect of degree of weight loss on health benefits. Obes Res 1995;3:211S-6S
3. National Heart, Lung and Blood Institute and The North American Association for the Study of Obesity. The Practical Guide to the Identification, Evaluation and Treatment of Overweight and Obesity in Adults, Bethesda, MD: National Institutes of Health; publication number 00-4084; 2000
4. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403 (Pubitemid 34437694)
5. The Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. One-year results of the Look AHEAD trial. Diabetes Care 2007;30:1374-1383
6. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Obesity Res 2004;12(9):1426-1434
7. Foster GD, Makris AP, Bailer BA. Behavioral treatment of obesity. Am J Clin Nutr 2005;82(Suppl):230S-5S
8. Lean MEJ. Sibutramine: a review of clinical efficacy. Int J Obes 1997;21:30S-6S (Pubitemid 27160697)
9. Sjostrom L, Rissanen A, Andersen T, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-172 (Pubitemid 28327800)
10. Cowley MA, Pronchuk N, Fan W, et al. Integration of NPY, AGRP, and Melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Nueron 1999;24:155-163
11. Mallinckrodt, Inc. Naltrexone hydrochloride tablet prescribing information. St Louis, MO; 2003
12. PubChem website. Available from: http://pubchem.ncbi.nlm.nih.gov [Accessed 13/9/08]
13. McEvoy GK. AHFS Drug Information. In: Bethesda MD, editor, American Society of Health-System Pharmacists, Inc.; 2008
14. Holtzman S. Behavioral effects of separate and combined administration of naloxone and d-amphetamine. J Pharm Exp Ther 1974;189:51-60
15. Holtzman S. Effects of narcotic antagonists on fluid intake in the rat. Life Sci 1975;16:1465-1470
16. Cole J, Berman N, Bodnar R. Evaluation of chronic opioid receptor antagonist effects upon weight and intake measures in lean and obese Zucker rats. Peptides 1997;18:1201-1207 (Pubitemid 28026890)
17. Cooper S. Palatability induced drinking after administration of morphine, naltrexone and diazepam in the non-deprived rat. Subst Alcohol Actions Misuse 1982;3:259-265
18. Bristol-Myers Squibb Company. Revia (naltrexone hydrochloride tablets). Labeling. 2001
19. Holister LE, Johnson K, Boukhabza D, et al. Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend 1981;8:37-41 (Pubitemid 11004811)
20. De Zwaan M, Mitchell JE. Opiate antagonists and eating behavior in humans: a review. J Clin Pharmacol 1992;32:1060-1072 (Pubitemid 23033657)
21. Fantino M, Hosotte J, Apfelbaum M. An opioid antagonist, naltrexone, reduces reference for sucrose in humans. Am J Physiol 1986;251:R91-6 (Pubitemid 16012578)
22. Bertino M, Beauchamp GK, Engelman K. Naltrexone, an opioid blocker, alters taste perception and nutrient intake in human. Am J Physiol 1991;261:R59-63
23. Atkinson RL, Berke LK, Drake CR, et al. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther 1985;38:419-422 (Pubitemid 16250316)
24. Mitchell JE, Morley JE, Levine AS, et al. High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry 1987;22:35-42 (Pubitemid 17229950)
25. Malcolm R, O'Neil PM, Sexauer JD, et al. A controlled trial of naltrexone in obese humans. Int J Obes 1985;9:347-353 (Pubitemid 16201361)
26. Maggio CA, Presta E, Bracco EF. Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men. Brain Res Bull 1985;14:657-661 (Pubitemid 16239703)
27. Spiegal TA, Stunkard AJ, Shrager EE, et al. Effects of naltrexone on food intake, hunger and satiety in obese men. Physiol Behav 1987;40:135-141 (Pubitemid 17096811)
28. Apotex Inc. Bupropion hydrochloride tablet prescribing information. Toronto, Ontario, Canada; 2006
29. Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. Neuropsychopharmacology 2007;32:822-834 doi:10.1038/sj.npp.1301155; published online 12 July 2006 (Pubitemid 46426174)
30. Zarrindast MR, Hosseini-Nia T. Anorectic and behavioural effects of bupropion. Gen Pharmacol 1988;19(2):201-204
31. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obesity Res 2001;9:544-551 (Pubitemid 33610175)
32. Anderson JW, Greenway FL, Fujiko K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10:633-642 (Pubitemid 135688262)
33. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002;10:1049-1056 (Pubitemid 135688922)
34. GlaxoSmithKline. Product information for Wellbutrin SR and XL. Available from: www.gsk.com
35. Bupropion and Naltrexone for the Treatment of Obesity poster: Available from: http://professional.diabetes.org/Content/Posters/2006/p1706-P.pdf [Accessed 13/9/08]
36. Orexigen® Therapeutics website: Available from: http://www.orexigen. com [Accessed 14/9/08]
37. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009;17(1):30-39 (Pubitemid 50324544)
38. Sinnayah P, Wallingford N, Evans A, Crowley MA. Bupropion and Naltrexone interact synergistically to decrease food intake in mice. Obesity 2007;15(#9 Suppl):A179
39. Greenway FL, Fujioka K, Gupta AK, et al. A Double-Blind, Placebo-, Bupropion- and Naltrexone-Controlled Study of the efficacy and safety of three doses of Naltrexone-Bupropion SR combination therapy in obesity: effects on total and visceral adipose tissue and CV risk markers. A85
40. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration mode. Diabetes 2005;54:1914-1925 (Pubitemid 40911252)
41. Grundy J, Dunayevich E, Guttadauria A, et al. Relative bioavailability of Sustained-Release (SR) versus Immediate-release (IR) Naltrexone formulations in healthy obese volunteers: implications for improved tolerability? Obesity 2008;16(Suppl 1):S217